Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate ...

Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 ...

Eli Lilly advances CRISPR collaboration with Scribe Therapeutics for neurological and neuromuscular disorders; European ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around 14,000 ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has cleared ...

After 'Reality Check' came out on Netflix, many are wondering where the winners—and the beloved runner-ups—are doing today.

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

While we had expected that Tesla will copy and paste most of the updates it made for the Chinese market version of the Model Y SUV, it appears the automaker is holding off on making those changes ...

Tesla's Model Y slots below the Model X as the brand's compact SUV. Sharing its underpinnings with the Model 3 sedan, the Model Y distinguishes itself with a higher roofline. Inside is where you see ...

Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building ...

A Body to Live In’ a fascinating trip into a transgressive culture ...